Titulo:
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes?
.
Guardado en:
2256-2877
2256-2915
7
2020-08-01
7
9
Ray Manneh Kopp - 2020
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
| id |
metarevistapublica_acho_revistacolombianadehematologiayoncologia_27_article_74 |
|---|---|
| record_format |
ojs |
| spelling |
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes? Hormone-sensitive metastatic prostate cancer: How should we treat our patients? Manneh Kopp, Ray 7 2 Núm. 2 , Año 2020 : Julio - Diciembre Artículo de revista Journal article 2020-08-01T00:00:00Z 2020-08-01T00:00:00Z 2020-08-01 application/pdf Asociación Colombiana de Hematología y Oncología (ACHO) Revista Colombiana de Hematología y Oncología 2256-2877 2256-2915 https://revista.acho.info/index.php/acho/article/view/74 10.51643/22562915.74 https://doi.org/10.51643/22562915.74 spa https://creativecommons.org/licenses/by-nc-nd/4.0 Ray Manneh Kopp - 2020 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0. 7 9 Francini E, Gray K, Xie W. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate Sep;78 (12):889-895. https://doi.org/10.1002/pros.23645 Gravis G, Boher J-M, Chen Y-H. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG_AFU15 studies. Eur Urol Jun;73 (6):847-855. https://dx.doi.org/10.1016%2Fj.eururo.2018.02.001 Sweeney C, Chen Y-H, Carducci M. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373:737-746. https://doi.org/10.1200/jco.2017.75.3657 James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet.2016 Mar 19;387 (10024): 1163-77. https://doi.org/10.1016/s0140-6736(15)01037 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B, et al. Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med 2017. Jul 27;377(4):352-360. https://doi.org/10.1056/nejmoa1704174 James N, de Bono J, Spears M. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017 Jul 27;377(4):338-35. https://goi.org/10.1056/NEJMoa1702900 Parker C, James N, Brawley C. Clarke N, Hoyle A, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 2018 Dec 1;392 (10162):2353-2366. https://doi.org/10.1016/s0140-6736(18)32486-3 Amstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide of placebo in men with metastatic hormonse-sensitive prostate cancer. J Cllin Oncol. 2019 Nov 10;37(32): 2974-2986. https://doi.org/10.1200/jco.19.00799 Davis I, Martin A, Stockler M, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019 Jul 11;381(2);121-131. https://doi.org/10.1056/nejmoa1903835 Chi K, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019 Jul 4;381(1):13-24. https://doi.org/10.1056/nejmoa1903307 https://revista.acho.info/index.php/acho/article/download/74/349 info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_b239 http://purl.org/redcol/resource_type/ARTEDIT info:eu-repo/semantics/publishedVersion http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Text Publication |
| institution |
ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA |
| thumbnail |
https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png |
| country_str |
Colombia |
| collection |
Revista Colombiana de Hematología y Oncología |
| title |
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes? |
| spellingShingle |
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes? Manneh Kopp, Ray |
| title_short |
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes? |
| title_full |
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes? |
| title_fullStr |
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes? |
| title_full_unstemmed |
Cáncer de próstata metastásico hormono-sensible : ¿Cómo deberíamos tratar a nuestros pacientes? |
| title_sort |
cáncer de próstata metastásico hormono-sensible : ¿cómo deberíamos tratar a nuestros pacientes? |
| title_eng |
Hormone-sensitive metastatic prostate cancer: How should we treat our patients? |
| author |
Manneh Kopp, Ray |
| author_facet |
Manneh Kopp, Ray |
| citationvolume |
7 |
| citationissue |
2 |
| citationedition |
Núm. 2 , Año 2020 : Julio - Diciembre |
| publisher |
Asociación Colombiana de Hematología y Oncología (ACHO) |
| ispartofjournal |
Revista Colombiana de Hematología y Oncología |
| source |
https://revista.acho.info/index.php/acho/article/view/74 |
| language |
spa |
| format |
Article |
| rights |
https://creativecommons.org/licenses/by-nc-nd/4.0 Ray Manneh Kopp - 2020 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0. info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 |
| references |
Francini E, Gray K, Xie W. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate Sep;78 (12):889-895. https://doi.org/10.1002/pros.23645 Gravis G, Boher J-M, Chen Y-H. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG_AFU15 studies. Eur Urol Jun;73 (6):847-855. https://dx.doi.org/10.1016%2Fj.eururo.2018.02.001 Sweeney C, Chen Y-H, Carducci M. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373:737-746. https://doi.org/10.1200/jco.2017.75.3657 James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet.2016 Mar 19;387 (10024): 1163-77. https://doi.org/10.1016/s0140-6736(15)01037 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev B, et al. Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med 2017. Jul 27;377(4):352-360. https://doi.org/10.1056/nejmoa1704174 James N, de Bono J, Spears M. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017 Jul 27;377(4):338-35. https://goi.org/10.1056/NEJMoa1702900 Parker C, James N, Brawley C. Clarke N, Hoyle A, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 2018 Dec 1;392 (10162):2353-2366. https://doi.org/10.1016/s0140-6736(18)32486-3 Amstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide of placebo in men with metastatic hormonse-sensitive prostate cancer. J Cllin Oncol. 2019 Nov 10;37(32): 2974-2986. https://doi.org/10.1200/jco.19.00799 Davis I, Martin A, Stockler M, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019 Jul 11;381(2);121-131. https://doi.org/10.1056/nejmoa1903835 Chi K, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019 Jul 4;381(1):13-24. https://doi.org/10.1056/nejmoa1903307 |
| type_driver |
info:eu-repo/semantics/article |
| type_coar |
http://purl.org/coar/resource_type/c_6501 |
| type_version |
info:eu-repo/semantics/publishedVersion |
| type_coarversion |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| type_content |
Text |
| publishDate |
2020-08-01 |
| date_accessioned |
2020-08-01T00:00:00Z |
| date_available |
2020-08-01T00:00:00Z |
| url |
https://revista.acho.info/index.php/acho/article/view/74 |
| url_doi |
https://doi.org/10.51643/22562915.74 |
| issn |
2256-2877 |
| eissn |
2256-2915 |
| doi |
10.51643/22562915.74 |
| citationstartpage |
7 |
| citationendpage |
9 |
| url2_str_mv |
https://revista.acho.info/index.php/acho/article/download/74/349 |
| _version_ |
1811200903483490304 |